Industry
Biotechnology
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Loading...
Open
3.97
Mkt cap
459M
Volume
438K
High
4.00
P/E Ratio
-6.11
52-wk high
6.71
Low
3.75
Div yield
N/A
52-wk low
3.56
Portfolio Pulse from
November 13, 2024 | 12:30 am
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 3:13 pm
Portfolio Pulse from Benzinga Newsdesk
August 16, 2024 | 3:28 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 10:09 am
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 8:40 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 8:21 pm
Portfolio Pulse from Benzinga Newsdesk
June 03, 2024 | 8:15 pm
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 8:28 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 3:46 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.